SCHEMBL5886408

SCHEMBL5886408

CCOc1cccc2c1C=CC(=O)C2=O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPRC P08575 4/20 0.49
CDC25B P30305 1/20 0.46
CTDSP1 Q9GZU7 1/20 0.43
TOP1 P11387 1/20 0.41
TTR P02766 1/20 0.41
MAPT P10636 6/20 0.40
KDM4E B2RXH2 3/20 0.40
MEN1 O00255 3/20 0.40
KMT2A Q03164 3/20 0.40
PABPC1 P11940 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
CYP2A6 P11509 1/20 0.40
GRK6 P43250 1/20 0.40
LMNA P02545 2/20 0.39
POLB P06746 2/20 0.39
RECQL P46063 2/20 0.39
PTPN1 P18031 2/20 0.39
ALDH1A1 P00352 2/20 0.39
BCHE P06276 1/20 0.39
THRB P10828 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5886287 0.81 TOP1 (0.58) PTPRCCDC25BTOP1MAPTKDM4E
SCHEMBL11919736 0.76 PTPRC (0.54) PTPRCCDC25BCTDSP1TTRMAPT
SCHEMBL30574283 0.76 TOP1 (0.66) PTPRCCDC25BCTDSP1TOP1TTR
SCHEMBL24194098 0.76 TOP1 (0.66) PTPRCCDC25BCTDSP1TOP1TTR
SCHEMBL27558184 0.75 PTPRC (0.55) PTPRCTOP1TTRMAPTKDM4E
SCHEMBL8759375 0.73 PTPRC (0.45) PTPRCCDC25BTOP1MAPTKDM4E
SCHEMBL5886239 0.71 PTPRC (0.53) PTPRCCDC25BTOP1MAPTKDM4E
SCHEMBL11478428 0.70 HPGD (0.46) PTPRCCDC25BMAPTKDM4EMEN1
SCHEMBL29018326 0.69 TOP1 (0.67) PTPRCCDC25BTOP1MAPTKDM4E
SCHEMBL6906659 0.69 TTR (0.68) PTPRCCDC25BCTDSP1TTRMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7132419-B2 Pharmaceutical compounds XENOVA LIMITED (GB) 2006-11-07 US disclosed
US-20050143383-A1 Pharmaceutical compounds XENOVA LIMITED (GB) 2005-06-30 US disclosed
US-20030139409-A1 Benzo[A] [phenazin-11-carboxamide derivatives and their use as joint inhibitors of topomerase I and II XENOVA LIMITED (GB) 2003-07-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050143383-A1 Pharmaceutical compounds CHRNA10, OPRM1, SCN10A PTPRC 3881/4885CDC25B 3748/4885CTDSP1 1526/4885
US-20030139409-A1 Benzo[A] [phenazin-11-carboxamide derivatives and their use as joint inhibitors of topomerase I and II TOP1, TOP2A, TOP2B PTPRC 2451/4885CDC25B 1637/4885CTDSP1 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.